Heineken, Diageo and Tequila Chamber Quietly Water Down WHO 'No Safe Level' Draft Ahead of Sept. 25 U.N. Vote - Alcohol Stocks Face Renewed Regulatory Risk

Letters and emails obtained by Reuters show the alcohol industry mounted a quiet but coordinated push this summer to blunt a tougher U.N.-backed public health text aimed at curbing booze-related harm. Big names and trade groups - from Mexico's tequila chamber to the Belgian Brewers and brewing giant Heineken (AMS: HEIN) - lobbied governments to water down measures that originally appeared in a draft aimed at non-communicable diseases ahead of the document's expected adoption on Sept. 25.

The fight is essentially about one sentence: the World Health Organization says there is "no safe level" of alcohol use, linking even modest drinking to higher cancer risk. Industry representatives argue the science is nuanced and have been trying to steer the U.N. language toward distinguishing moderate drinking from harmful consumption. The result: some originally firm calls - like explicit tax hikes and advertising bans - were softened in later drafts to "consider" measures and to focus advertising controls on minors.

That pushback wasn't subtle. Mexico's National Chamber of the Tequila Industry reportedly urged its government to lobby others to remove WHO-backed proposals such as higher taxes and retail restrictions. Heineken's outreach suggested swapping a broad ad ban for rules targeting youth advertising. Belgian Brewers flagged a national minister for taking what they called "radical positions" in the U.N. talks.

Industry groups have been stepping up their firepower. The International Alliance for Responsible Drinking has boosted funding and activity to compete in the science and policy debate. Diageo (LSE: DEO) even advertised for a senior lobbying role this year, saying the WHO pressure presented "an unprecedented challenge." Carlsberg's CEO has publicly argued the industry needs to tell a more positive story about moderate drinking's social value.

WHO officials pushed back publicly, saying the agency has intensified its alcohol-related publications since 2022 and must take a hard line on major drivers of disease. The agency also acknowledged the negotiation process had been subject to intense lobbying.

What this means for market players: the clash raises regulatory and headline risk for listed alcohol names. Policy language that swings from explicit mandates to vague "considerations" matters - it alters the near-term threat of higher excise taxes, tighter retail rules or broad advertising bans, all of which feed into revenue and margin outlooks. At the same time, larger reputational and ESG pressures are in play as health agencies amplify messaging that downplays any safety of drinking.

Expect volatility around newsflow tied to the U.N. agreement and any fresh WHO reports. Lobbying success can dull near-term regulatory risk, but persistent public-health messaging also changes consumer sentiment over time - particularly among cash-conscious and health-aware cohorts trimming discretionary spending on alcohol. Corporate moves - more aggressive public relations, science funding, and government engagement - are now part of the playbook for the sector.

Whether the softened language in the latest draft is a temporary reprieve or a signal that companies have gained lasting influence will be clearer after the September vote. Will regulators push back again, or does this mark the high-water mark for industry influence? The answer will matter for valuations and volatility in the months ahead.